Revenue Growth
Total revenues of $239.7M in Q2, up 14.7% year-over-year from $209.0M and up 1.5% sequentially, driven by higher member months and capitation rates.
Adjusted EBITDA Turnaround and Margin Target Achieved
Adjusted EBITDA of $22.2M in Q2 (vs. $5.9M in 2025 and $17.6M in 2026), yielding an adjusted EBITDA margin of 9.2%, exceeding the company's intermediate-term 8%–9% target and improving from 2.8% in 2025 (a ~640 bps increase).
Net Income Improvement
Net income of $11.8M in Q2 versus a net loss of $13.5M in 2025; net income per share of $0.08 with ~136.4M diluted shares outstanding.
Enrollment and Member Month Growth
Census of ~8,010 participants as of 12/31/2025 (7.1% growth vs. 2025; 1.5% sequential). Member months of 23,960 in Q2, up ~7.9% year-over-year and ~2% sequentially, aided by reinstatements after Medicaid redetermination work.
Improved Contribution Margin and Cost Management
Central/center-level contribution margin of $52.8M in Q2 (22% of revenue), up ~430 basis points vs. 17.7% in 2025. Stronger medical cost management noted, with decreases in cost-per-participant driven by lower permanent nursing facility utilization and pharmacy cost reductions from insourcing.
Raised Fiscal 2026 Guidance
Updated FY26 guidance raised: member months 92,900–95,700; total revenue $925M–$950M; adjusted EBITDA $70M–$75M; ending census unchanged at 7,900–8,100, reflecting confidence from first-half results.
Stronger Operating Cash and Balance Sheet Position
Quarter-end liquidity of $83.2M cash plus $42.8M short-term investments, total debt of $69.9M, positive operating cash flow of $21.4M in the quarter, and modest capex of $2.4M.
Operational and Governance Progress
Company reported disciplined execution: improved revenue integrity (Medicaid eligibility/redeterminations), standardized center operations, lower corporate G&A (down 5.3% vs. 2025 and 12.1% vs. Q1 2026), pharmacy insourcing stabilization, and board governance changes to strengthen oversight.